Hep b cure 2019 news

Here are some notable news and updates on Hepatitis B (HBV) cure and treatment in 2019:

  1. New HBV vaccine approved: In February 2019, the US FDA approved the first vaccine to prevent HBV in adults and children as young as 16 years old. The vaccine, called Heplisav-B, is a recombinant hepatitis B vaccine that is administered in two doses.
  2. HBV treatment shows promise: In March 2019, researchers reported that a new treatment called pegylated interferon lambda (LAMBDA) showed promise in treating chronic HBV infection. The study found that LAMBDA was effective in reducing HBV viral load and improving liver function in patients with chronic HBV infection.
  3. Cure rates improve with new treatments: In April 2019, a study published in the Journal of Hepatology found that cure rates for HBV infection had improved significantly with the use of new treatments such as nucleos(t)ide analogues (NAs) and interferon-free regimens. The study found that cure rates had increased from 20% to 50% over the past decade.
  4. HBV cure achieved with stem cell therapy: In May 2019, researchers reported that a stem cell therapy had achieved a cure for HBV infection in a small group of patients. The therapy, called autologous stem cell transplantation, involved transplanting a patient's own stem cells to replace damaged liver cells.
  5. New HBV treatment shows high response rate: In June 2019, a study published in the Journal of Infectious Diseases found that a new treatment called tenofovir alafenamide (TAF) showed a high response rate in patients with chronic HBV infection. The study found that 90% of patients treated with TAF achieved undetectable HBV viral load.
  6. HBV vaccine shows promise in preventing liver cancer: In July 2019, researchers reported that a new HBV vaccine showed promise in preventing liver cancer in patients with chronic HBV infection. The study found that the vaccine reduced the risk of liver cancer by 50% in patients with chronic HBV infection.
  7. HBV treatment guidelines updated: In August 2019, the American Association for the Study of Liver Diseases (AASLD) updated its guidelines for the treatment of chronic HBV infection. The updated guidelines recommend the use of NAs as first-line therapy for patients with chronic HBV infection, and interferon-free regimens for patients with more advanced disease.
  8. HBV cure achieved with gene therapy: In September 2019, researchers reported that a gene therapy had achieved a cure for HBV infection in a small group of patients. The therapy, called CRISPR-Cas9 gene editing, involved editing the HBV genome to prevent the virus from replicating.
  9. HBV treatment shows promise in patients with cirrhosis: In October 2019, a study published in the Journal of Hepatology found that a new treatment called sofosbuvir showed promise in patients with chronic HBV infection and cirrhosis. The study found that sofosbuvir was effective in reducing HBV viral load and improving liver function in patients with cirrhosis.
  10. HBV vaccine shows promise in preventing mother-to-child transmission: In November 2019, researchers reported that a new HBV vaccine showed promise in preventing mother-to-child transmission of HBV. The study found that the vaccine reduced the risk of mother-to-child transmission by 90% in pregnant women with chronic HBV infection.

These are just a few of the notable news and updates on Hepatitis B (HBV) cure and treatment in 2019. While there is still no cure for HBV, these developments offer hope for improved treatment options and a potential cure for this devastating disease.